
    
      This was a multicenter, open-label, dose-finding clinical trial examining the safety and PK
      of once or twice daily motesanib administered with CP or with CP and panitumumab in
      chemotherapy na√Øve patients, and with panitumumab in patients with no more than one prior
      chemotherapy regimen for NSCLC.

      Participants were enrolled into the Panitumumab + Paclitaxel + Carboplatin + Motesanib once a
      safe and tolerable dose of AMG 706 was established in the other treatment arms.
    
  